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Merkel Cell Polyomavirus Status Is Not Associated
with Clinical Course of Merkel Cell Carcinoma
David Schrama1,2, Wiebke K. Peitsch3, Marc Zapatka4, Hermann Kneitz2, Roland Houben2, Steffi Eib2,
Sebastian Haferkamp2, Patrick S. Moore5, Masahiro Shuda5, John F. Thompson6, Uwe Trefzer7,
Claudia Pfo¨hler8, Richard A. Scolyer9 and Ju¨rgen C. Becker1
The majority of Merkel cell carcinomas (MCCs) are associated with the recently identified Merkel cell
polyomavirus (MCV). However, as it is still unclear to which extent the presence of MCV impacts tumor
characteristics or clinical outcome, we correlated the MCV status of tumor lesions obtained from 174 MCC
patients including 38 MCC patients from Australia and 138 MCC patients from Germany with clinical
characteristics, histomorphology, immunohistochemistry, and course of the disease. MCV DNA was present in
86% of MCCs and, in contrast to previous reports, no significant difference in MCV prevalence was present
between Australian and German MCC cases. When patients were stratified according to their MCV status, only
tumor localization (P¼ 0.001), gender (P¼ 0.024), and co-morbidity, i.e., frequency of patients with previous skin
tumors (P¼ 0.024), were significantly different factors. In contrast, year of birth and diagnosis, age at diagnosis,
or histological type and features representing the oncogenic phenotype such as mitotic rate or expression of
p16, p53, RB1, and Ki67 were not significantly different between MCV-positive and MCV-negative MCCs. MCV
status also did not influence recurrence-free, overall, and MCC-specific survival significantly. In summary,
although MCV-positive and MCV-negative MCCs may have different etiologies, these tumors have comparable
clinical behaviors and prognosis.
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INTRODUCTION
Merkel cell carcinoma (MCC) is a rare, aggressive neuroen-
docrine carcinoma of the skin. Currently, MCC accounts for
only a small fraction of cutaneous malignancies, with age-
adjusted incidence rates of 0.18 to 0.41 per 100,000 people
(Albores-Saavedra et al., 2009). Noteworthy, however, the
incidence of MCC appears to have tripled from 1986 to 2001
(Hodgson, 2005). The typical clinical course of MCC
progression includes a high rate of locoregional recurrences,
nodal invasion, and distant metastases (Krasagakis and Tosca,
2003). In fact, MCC is the most aggressive skin malignancy
with more than one-third of MCC patients dying from this
cancer; i.e., it is at least twice as lethal as melanoma.
Recently, a new type of human polyomavirus was
identified in MCC and named Merkel cell polyomavirus
(MCV) (Feng et al., 2008). Notably, the integration of MCV
before clonal expansion and at distinct sites in different MCC
tumors sustain the assumption that viral proteins are causal
for tumorigenesis (Feng et al., 2008; Sastre-Garau et al.,
2009). Moreover, we could recently demonstrate that MCV-
positive MCC cells critically depend on the expression of the
T antigens reflecting oncogene addiction to T-antigen
expression (Houben et al., 2010b).
Meanwhile, many reports have confirmed the presence
of MCV DNA in tumor samples of most MCC patients (Kassem
et al., 2008; Becker et al., 2009; Sastre-Garau et al., 2009).
Nevertheless, a few exceptions have also been reported: (1) in
Australian patients, only approximately one-fourth of patients
harbored detectable MCV DNA in one report (Garneski et al.,
2009); and (2) in two American patients, MCV DNA was
detectable in the primary but not in a corresponding
metastatic tumor (Andea et al., 2009). Moreover, whether
the presence of MCV DNA in MCC impacts tumor character-
istics or clinical behavior remains controversial (Becker et al.,
2009; Sihto et al., 2009; Handschel et al., 2010; Bhatia et al.,
2010a, 2010b; Houben et al., 2010a).
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The previous observations in combination with the
assumption of a causal role of MCV for the etiology of
MCC prompted us to compare the frequency of MCV in
Australian and European MCC patients and to test the
concordance of MCV status in multiple samples of individual
patients. Furthermore, we compared clinical and histological
parameters of virus-positive and -negative cohorts of this
large MCC cohort comprising both German and Australian
patients.
RESULTS
Patient characteristics and MCV status
A total of 185 samples of 136 European and 49 samples from
38 Australian MCC patients were analyzed. Detailed patient
characteristics are given in Table 1. The PCR-based MCV
status analysis revealed that 85.3% (116 of 136) of the
European MCCs and 86.8% (33 of 38) of the Australian MCCs
were positive, resulting in a combined total of 85.6% for all
analyzed tumors (Table 1). Estimated copies of viral genome
per cell waso0.1 in only 9 patients, ranged between 0.1 and
10 in 110, and was 410 for 30 of our 149 positive patients
(data not shown). Notably, MCV-PCR-positive tumors were
also positive for MCV large T-antigen (LT) protein expression
(Figure 1).
In all 33 MCV-positive and 4 MCV-negative MCC patients
with multiple samples available for analysis, the MCV status
was concordant (data not shown). Moreover, in one patient,
sequence analysis of the LT gene in tumor cells derived from
four different lesions demonstrated the same stop codon
mutation in all four lesions (data not shown).
Comparison of MCV-negative and MCV-positive tumors
Next, we compared the histological and clinical character-
istics of tumors with different viral status on the total patient
population. This comparison clearly demonstrated that both
cohorts were similar in many aspects: There were no
significant differences in microscopic characteristics such as
histological type, microanatomic compartment involved,
mitotic rate, lymphocyte infiltrate, and cytokeratin 20
staining, or clinical features, i.e., stage at diagnosis, age at
diagnosis, year of diagnosis, year of birth, and presence or
absence of immune suppression (Table 1). However, body
site distribution of primary MCC was significantly associated
with the MCV status; the MCV-positive tumors were more
frequently located on the extremities and less often located
on the trunk than their virus-negative counterparts (Table 1;
P¼0.001). Furthermore, the percentage of female patients
was significantly higher among the MCV-positive patients
(P¼0.024), and virus-negative patients had more often a
previous history of other skin cancers (P¼0.024).
To evaluate if oncogenic viral proteins encoded by MCV
impact cell cycle regulation, apoptosis, or mitogenic signal-
ing, we scrutinized MCV-positive and -negative tumors for
expression and phosphorylation of a number of proteins
representing these pathways. In detail, protein expression
analyses of p16, p53, RB1, pERK, and Ki67 for a subgroup of
tumors (45–53 randomly selected patients per staining)
revealed that p16 and RB1 were highly frequent in tumor
cells, pERK was rare, whereas the frequencies for p53 and
Ki67 were quite variable between patients. Nevertheless,
there was no obvious differences between the MCV-negative
and MCV-positive tumors (Figure 2; Houben et al., 2010a).
No impact of MCV status on clinical behavior
For 127 of the patients, detailed information was available to
evaluate the impact of MCV status on recurrence-free,
overall, as well as MCC-specific survival by univariate and
multivariate analyses. For recurrence-free survival, there was
no significant difference between the Kaplan–Meier curves
of MCV-positive or -negative MCC patients, respectively
(Figure 3a; log-rank (Mantel–Cox) test; P¼0.158). Accord-
ingly, the univariate hazard ratios (HRs) for virus-positive
patients did not differ significantly (HR¼1.753; 95% con-
fidence interval (CI) 0.794–3.870; P¼ 0.165), or when
adjusted to gender, age, and tumor stage at diagnosis
(HR¼ 1.701; 95% CI 0.748–3.868; P¼ 0.205) or additionally
to localization of primary tumor, lymphocyte infiltrate, and
microanatomic compartment involved (HR¼ 2.778; 95% CI
0.930–8.298; P¼ 0.067)–all factors that are known to have an
impact on clinical course (Andea et al., 2008; Albores-
Saavedra et al., 2009; Table 2).
The overall median survival was 29.4 months for MCV-
negative and 57 months for MCV-positive MCC patients
(Figure 3b). But similar to recurrence-free survival, both the
Kaplan–Meier curves (P¼ 0.468) and the HRs were not
significantly different (HR¼0.750; 95% CI 0.344–1.636 for
virus-positive patients; P¼ 0.470). In addition, both multi-
variate analyses, i.e., adjusted to gender, age, and tumor
stage (HR¼0.981; 95% CI 0.423–2.273; P¼ 0.964) or
additionally for lymphocyte infiltrate, microanatomic com-
partment involved, and localization of the primary tumor
(HR¼ 1.861; 95% CI 0.519–6.679; P¼ 0.341) could not
demonstrate a significant difference in overall survival
between MCV-positive and -negative MCC patients. Next,
we focused on MCC-specific survival, i.e., only patients who
died with advanced disease were regarded as an event. Still,
the Kaplan–Meier curves and the HRs of MCV-positive and
-negative patients did not display a significant difference
(Figure 3c and Table 3). Similarly, adjusting for the various
factors discussed above in multivariate analyses did not result
in significantly different HRs for MCV status (Table 2).
DISCUSSION
Until the recent description of the MCV, the pathogenesis of
MCC was poorly understood. The demonstration that the
MCV genome was integrated in the tumor cell DNA in six of
eight tumors positively tested rendered MCC the first cancer
with an integrated polyomavirus genome (Feng et al., 2008).
Noteworthy, this integration indicated a causative role of
MCV in the induction of MCC, especially as the patterns of
integration demonstrate that viral infection precedes clonal
expansion of the tumor cells (Feng et al., 2008). Indeed, we
also observed concordant MCV results and sequences
(performed only for one patient) for different samples of the
same patient sustaining that the integration of the viral
genome into the host cell is an early event occurring before
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Table 1. Patient and tumor characteristics
Variable MCC total MCV positive MCV negative P-value*
Number of patients 174 149 (85.6%) 25 (14.4%)
Analyzed samples 234 203 31
Mean age (IQR) (years) 73.3 (66–81) 73 (66–80) 75.1 (68.5–82.5) 0.3546
Mean follow-up (IQR) (months) 24.9 (4.8–34) 24.9 (4.5–34.1) 25.2 (5.2–30.9) 0.8947
Mean year of birth (IQR) 1929 (1922–1937.5) 1929.4 (1922–1938) 1927.5 (1919–1934) 0.4506
Mean year of diagnosis (IQR) 2002.6 (1999.8–2006) 2002.6 (2000–2006) 2002.9 (1999–2007) 0.7107
Gender
Male 88 (56.4%) 70 (52.6%) 18 (81%) 0.0248
Female 68 (43.6%) 63 (47.4%) 5 (19%)
Stage at diagnosis1,2
Stage I 80 (61.1%) 69 (62.7%) 11 (52.3%) 0.1708
Stage II 47 (35.9%) 39 (35.5%) 8 (38.1%)
Stage III 4 (3.1%) 2 (1.8%) 2 (9.5%)
Localization1
Head/neck 52 (46.4%) 41 (44.6%) 11 (55%) 0.0018
Trunk 16 (14.3%) 9 (9.8%) 7 (35%)
Extremities 44 (39.3%) 42 (45.7%) 2 (10%)
Histological type
Small cell 9 (8.4%) 6 (6.6%) 3 (18.8%) 0.1758
Intermediate 67 (62.6%) 59 (64.8%) 8 (50%)
Trabecular 31 (29%) 26 (28.6%) 5 (31.3%)
Microanatomic compartment
Dermis 8 (7.7%) 8 (9.2%) 0.4548
Subcutis 95 (91.3%) 78 (89.7%) 17 (100%)
Deeper 1 (1%) 1 (1.1%)
Mitotic rate1
Intermediate 48 (43.6%) 43 (46.2%) 5 (29.4%) 0.2888
High 62 (56.4%) 50 (53.8%) 12 (70.6%)
Lymphocyte infiltrate1,3
Yes 46 (41.4%) 39 (41.5%) 7 (41.2%) 0.9998
No 65 (58.6%) 55 (58.5%) 10 (58.8%)
Immunosuppression1,4
Yes 8 (10.5%) 6 (9.7%) 2 (14.3%) 0.6358
No 68 (89.5%) 56 (90.3%) 12 (85.7%)
Previous history of skin cancer1,5
Yes 22 (25.6%) 14 (20%) 8 (50%) 0.0248
No 64 (74.4%) 56 (80%) 8 (50%)
Cytokeratin 207
Positive 165 (98.8%) 144 (99.3%) 21 (95.5%) 0.2478
Negative 2 (1.2%) 1 (0.7%) 1 (4.5%)
Abbreviations: IQR, interquartile range; MCC, Merkel cell carcinoma; MCV, Merkel cell polyomavirus.
1The respective characteristics were not documented for all patients.
2Staging was performed according to Boyle et al. (1995): stage I: localized disease; stage II: local–regional metastases; stage III: distant metastases.
3The presence of a lymphocyte infiltrate was determined by hematoxylin and eosin (HE) staining. Only lymphocytes infiltrating the tumor were considered.
4Patients were regarded immunosuppressed when they had received immunosuppressing drugs due to organ transplantation or HIV infection.
5The most common skin cancers, i.e., basal cell carcinoma, squameous cell carcinoma, and melanoma, were considered.
*P-values were calculated by:
6t-test (when values were normally distributed) or
7Mann–Whitney test to compare values of two independent groups or
8Fisher’s exact test for contingency tables.
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acquiring metastatic potential. The causative role of MCV in
the pathogenesis of MCC was further substantiated by our
recent finding that MCV-positive MCC cell lines require
T-antigen expression to maintain proliferation and survival
(Houben et al., 2010b). Although the transforming capacity of
MCV has still to be proven formally, these observations
fueled the discussion if MCV-positive and MCV-negative
MCCs can still be regarded as the same tumor entity.
Up to date, only a few studies have addressed the
differences between MCV-positive and MCV-negative MCCs
with respect to tumor and patients characteristics or course of
disease (Garneski et al., 2009; Sihto et al., 2009; Andres
et al., 2009b). As MCC is a rare cancer, patient numbers in
the reported studies are limited. Thus, to establish the impact
of MCV on MCC, several studies are needed to eventually
allow a meta-analysis. Therefore, we analyzed the presence
of MCV in 174 MCC patients from Europe and Australia and
compared their clinical and immunohistological features
according to their MCV status. We included Australian
patients in this study as it was previously reported that the
presence of MCV DNA is much lower in Australia when
compared with North America or Europe (Garneski et al.,
2009).
In the presented cohort, 86% of the MCCs from either
continent harbored MCV DNA. For the European patient
cohort, the observed frequency is in accordance with the
reported frequencies (Kassem et al., 2008; Sastre-Garau et al.,
2009). In contrast, the frequency for the Australian patients is
much higher than previously reported: in the study by
Garneski et al. (2009), only 5 (24%) of 21 Australian MCC
specimens were virus positive. Notably, these samples were
obtained from the same group who generated a series of MCC
cell lines of which all four tested cell lines were negative for
MCV (Shuda et al., 2008; and own observation). Analysis of
the expression of MCV-derived LT on the protein level
confirmed the high frequency of MCV-positive patients in our
Australian patient cohort. These different frequencies in the
two studies can neither be explained by the geographical
regions from which the samples were obtained (Brisbane vs.
Sydney) nor the kind of MCC tumors (in both series,B50% of
the samples were metastases). Thus, these differences may be
either due to (1) chance, (2) technical factors such as different
MCV assays or quality of DNA, or (3) differences in the year
Figure 1. Immunohistological staining for large T-antigen in Merkel cell
carcinoma (MCC) tumors. Sections of paraffin-embedded tumors were
stained for large T-antigen expression. Examples of (a) a Merkel cell
polyomavirus (MCV)-negative tumor and (b–d) different levels of large
T-antigen protein expression in Australian patients are depicted.
Bar¼100 mm.
p16
MCV
negative
MCV
positive
RB1 p53 Ki67
Figure 2. Immunohistochemical characteristics of virus-negative and -positive Merkel cell carcinoma (MCC) tumors. Exemplary results of p16, RB1, p53, and
Ki67 staining in Merkel cell polyomavirus (MCV)-negative and MCV-positive MCC tumors. Generally, almost all Merkel carcinoma cells express p16 and RB1,
whereas the expression of p53 and Ki67 varies between patients, however, irrespective of the MCV status. Bar¼ 100 mm.
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of diagnosis, as the samples in the study of Garneski et al.
(2009) were obtained in the 1990s, whereas our samples
were more recently obtained (median year of diagnosis for
the Australian patient cohort is 1999).
The comparative study of 149 MCV-positive and 25 MCV-
negative MCC patients revealed three significant differences,
of which body site distribution of the primary MCCs is the
most significant factor. This observation is in accordance with
the report of Sihto et al. (2009) that MCV-positive tumors
were less often localized at the trunk. These authors
speculated that MCV might be transmitted by physical
contact. An alternative explanation that would explain the
high frequency of MCV-positive tumors located on the head
and the extremities, i.e., sun-exposed areas, is that UV
irradiation is involved in MCV-driven oncogenesis: integrated
MCV genomes in MCC harbor mutations prematurely
truncating the LT protein, thereby eliminating the helicase
domain that should stabilize the integration of the viral
genome. A large study of whether these truncating mutations
bear a UV signature could help to clarify this notion.
Another significant difference between virus-positive and
virus-negative cases in our cohort is the higher frequency of
females among the virus-positive patients; however, when
adjusted for multiple testing, this factor is not significant
anymore (P¼0.308). Nevertheless, it should be noted that
when all studies with reported gender distribution for the
MCV status—including this study—are combined, 249
(76.9%) of 324 male and 268 (85.3%) of 314 female MCC
patients were virus positive (Feng et al., 2008; Foulongne
et al., 2008; Kassem et al., 2008; Busam et al., 2009;
Nakajima et al., 2009; Sastre-Garau et al., 2009; Sihto et al.,
2009; Varga et al., 2009; Andres et al., 2009a; Fischer et al.,
2010; Handschel et al., 2010; Bhatia et al., 2010b). Although
a sex imbalance could be biologically explained, more
studies are needed to confirm or decline an association of
MCV status with sex.
In a recently published study with 114 patients from
Finland, patients with MCV-positive MCCs had a better
overall survival than those with MCV-negative tumors (Sihto
et al., 2009). Similarly, in a small study of 23 patients, it was
observed that patients with more MCV copies per cell were
characterized by a better survival (Bhatia et al., 2010a). In
contrast, in a recent study of 44 patients (Handschel et al.,
2010), as well as in the large patient cohort reported here, this
association of MCV status with survival could not be
confirmed. Indeed, we could not detect significant differ-
ences in regression-free survival, overall survival, or MCC-
specific survival when analyzed either in a univariate or
multivariate fashion. The discrepancy regarding prognostic
impact of the MCV status between the study of Sihto et al.
(2009) can at least in part be explained by the circumstance
that most of the MCC patients from their cohort were female
(70%), a surprising gender distribution as all previous
reports observed a male predominance in MCC patients.
Accordingly, in our study cohort, only 43.6% of the patients
were women. Thus, the patient cohort analyzed by Sihto
et al. (2009) seems somehow exceptional that might be,
for example, because of geographic or lifestyle aspects; a
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Figure 3. Kaplan–Meier curves for recurrence-free, overall, and Merkel cell
carcinoma (MCC)-specific survival. MCC patients were stratified upon the
molecular detection of Merkel cell polyomavirus (MCV) in their tumors. The
(a) recurrence-free, (b) overall, and (c) MCC-specific survival rates are
depicted for 60 months. Beneath each curve the patients at risk are given.
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notion strengthened by a study of Danish MCC patients
in which the majority, i.e. 60%, were female (Kaae
et al., 2010).
There are a couple of limitations to our study. As for most
retrospective studies, complete clinical information was not
available for all patients. Notably, the scrutinized patient
cohort displays similar characteristics as the recently pub-
lished large study on MCC patients by Albores-Saavedra et al.
(2009). Indeed, our patient cohort is only slightly younger
(73.3 compared with a calculated age of 74.6) and has a little
higher frequency of females (43.6% compared with 38.5%).
Importantly, in both studies the 5-year survival rate isB60%.
The second problem, which is also inherent for studies on
rare diseases analyzing an uneven distributed factor, is the
limited power of the performed statistics. In fact, the power of
our MCC-specific survival analysis is, for example, only 65%.
Notably, to increase the power to over 80%, we would have
to include at least another 80 events, which is for such a rare
cancer an almost impossible challenge. Nevertheless, the
power to observe the same effect of MCV status on survival as
Table 2. Univariate and multivariate HRs for MCV status
Univariate HR (95% CI) P-value Multivariate 1 HR (95% CI)1 P-value Multivariate 2 HR (95% CI)2 P-value
Recurrence-free survival
MCV negative 1 1 1
MCV positive 1.753 (0.794–3.870) 0.165 1.701 (0.748–3.868) 0.205 2.778 (0.930–8.298) 0.067
Overall survival
MCV negative 1 1 1
MCV positive 0.750 (0.344–1.636) 0.470 0.981 (0.423–2.273) 0.964 1.861 (0.519–6.679) 0.341
MCC-specific survival
MCV negative 1 1 1
MCV positive 1.054 (0.362–3.066) 0.924 1.601 (0.477–5.371) 0.446 3.664 (0.665–20.183) 0.136
Abbreviations: CI, confidence interval; HR, hazard ratio; MCC, Merkel cell carcinoma; MCV, Merkel cell polyomavirus.
1HR of MCV status was adjusted to gender, age, and stage; n=122.
2HR of MCV status was adjusted to gender, age, stage, lymphocyte infiltrate, involved microanatomic compartment, and localization of the primary tumor;
n=76.
Table 3. Univariate and multivariate HRs for MCC-specific survival
Univariate HR (95% CI) P-value Multivariate HR (95% CI)1 P-value
Gender
Female 1 1
Male 1.615 (0.673–3.874) 0.283 1.963 (0.769–5.001) 0.158
Age2 0.978 (0.938–1.019) 0.281 1.014 (0.972–1.057) 0.530
Stage
I 1 1
II 3.838 (1.597–9.22) 0.003 4.286 (1.659–11.076) 0.003
III 17.943 (4.29–75.042) o0.001 26.587 (5.38–131.373) o0.001
MCV status
Negative 1 1
Positive 1.054 (0.362–3.066) 0.924 1.601 (0.477–5.371) 0.446
Abbreviations: CI, confidence interval; HR, hazard ratio; MCC, Merkel cell carcinoma; MCV, Merkel cell polyomavirus.
1HR was adjusted to all the other factors.
2Age was analyzed as a continuous variable.
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described by Sihto et al. (2009) is over 80% for our patient
cohort (data not shown).
In most of the factors analyzed, we could not observe
significant differences between virus-negative and -positive
MCCs. Accordingly, it seems prudent to state that the MCC
viral status does not have a major impact on the course of
MCC. This notion is further corroborated by the fact that all
established prognostic factors apart from gender and body
side distribution were equally distributed between MCV-
positive and MCV-negative patients. Moreover, when scru-
tinizing the expression of p16, RB1, p53, or the proliferation
marker Ki67, no relevant differences were observed. In
summary, although MCV-positive and -negative MCCs are
likely to have different etiologies, they seem to share a very
comparable clinical behavior, prognosis, and aberrations in
signal transduction. Thus, future studies are warranted
to establish the etiology of both MCV-positive and -negative
MCCs. In this respect, the very recent discovery of new
polyomavirus members also present in human skin should be
noted (Schowalter et al., 2010; van der Meijden et al., 2010).
MATERIALS AND METHODS
Patients
Archived paraffin-embedded tumor samples from a total of 174 MCC
patients were collected from Germany (136 patients) or Australia (38
patients). All tumors had been excised for therapeutic reasons. MCCs
were defined by histology and immunohistochemistry using
antibodies to CK20, CD56, and TTF1. The presence of MCC in the
samples had been demonstrated by routine histology and confirmed
by an independent pathologist. The study was approved by the
respective institutional review boards, and was in accordance with
the Declaration of Helsinki Principles.
DNA isolation and MCV detection
Genomic DNA was isolated from serial sections using a DNA
Isolation Kit (Qiagen, Hilden, Germany). The samples were analyzed
for the presence of MCV using a TaqMan assay specific for the MCV
T antigen and VP1 gene. Taqman primer and probe for T antigen
were described previously (Becker et al., 2009); for VP1, they
were designed with Primer Express (Applied Biosystems, Darmstadt,
Germany): fw: 50-GCCTTTTGAGGTCCTTTCAGTG-30, rv: 50-ACTGT
TTACCCAAAGCCCTCTG-30 and the probe: FAM-50-CGCCTTGCCC
TTATCCTGCTGATTACTTTG-30-BHQ1. LINE1, a highly repetitive
DNA element, served as DNA control. The relative presence of MCV
genome in the samples was determined by the DDCt method where
DNA of a MCV-positive cell line with at least two copies of MCV
genome served as calibrator allowing only an estimation of copy
numbers (Houben et al., 2010a). MCV positivity was concluded
when the relative expression of LT was larger than our cut point
determined by bystander positivity in other cancers (Becker et al.,
2009). Real-time PCR for VP1 did not have to be positive, as this
region might be lost by integration into the genome (Schrama,
own unpublished observation).
Immunohistochemistry
For immunohistochemical detection of LT in paraffin-embedded
tissues, slides were deparaffinized, and endogeneous peroxidase was
blocked with hydrogen peroxide. Subsequently, epitope retrieval
was performed using EDTA antigen retrieval buffer (Sigma-Aldrich,
Schnelldorf, Germany). After blocking with protein block (Dako,
Hamburg, Germany), samples were incubated with CM2B4
(1:2,000; Shuda et al., 2009) for 30minutes at room temperature,
washed twice with Tris-buffered saline buffer, incubated with Mouse
Envision Polymer (Dako) for 30minutes, and incubated with
Nova Red (Vector, Burlington, Canada). Finally, slides were rinsed
with deionized water, counterstained with hematoxylin (DAKO
S3309), and mounted in Shandon Ez Mount (Thermo Scientific,
Braunschweig, Germany).
Antigen retrieval for RB1, p16, p53, pERK, and Ki67 staining was
performed by incubation with citrate buffer (DAKO), pH 6.0 (RB1,
p16, pERK, and Ki-67) or pH 9.0 (p53), for 20minutes at 90 1C,
followed by rinsing with distilled water and twice with phosphate-
buffered saline (DAKO, S3024). After incubation with the Blocking
Solution (DAKO, S2023) for 10minutes at room temperature
and two washing steps with phosphate-buffered saline, anti-RB1
(RB-1441-PO, DAKO), anti-p16 (Clone 16P04, Neomarkers,
Fremont, CA), anti-p53 (DO-7, Dako), anti-pERK (clone E10; Cell
Signaling, Beverly, CA), or anti-Ki67 antibodies (MIB-1, DAKO) were
added to the sections and incubated overnight at 4 1C (pERK), at
room temperature for 60minutes (RB1) or 25minutes (all others).
After two washes with phosphate-buffered saline, biotinylated
multispecies-specific secondary antibodies (Dako, K5003) were
applied for 30minutes. Bound antibodies were visualized using
streptavidin–horseradish peroxidase (DAKO K5003) and Vector Vip
(Vector) as peroxidase substrate according to the manufacturer’s
guidelines. Finally, the nuclei were stained with hematoxylin.
Statistical analysis
Statistical analysis was performed with PASW 18 (IBM, Munich,
Germany), and the bases for the analyses were the patients.
Distributions between MCV-positive and MCV-negative patients
were compared with the t-test, when the respective factor passed the
Shapiro–Wilk test for normality or alternatively with the Mann–Whit-
ney U-test. P-values for contingency tables were calculated using
Fisher’s exact test. P-values were not corrected for multiple testing
and were considered significant when o0.05. Kaplan–Maier curves
were compared by the Mantel–Cox log-rank test. Univariate and
multivariate HRs were calculated by Cox proportional hazards survival
regression analysis (Lawless, 1982; Kleinbaum, 1996). All applied
models were tested for and passed the proportional-hazard assumption
based on Schoenfeld residuals. The power calculations were
performed in R (www.r-project.org) using the cpower function based
on George–Desu method from the Hmisc package. Mortality rates and
percent reduction in mortality were calculated from the studies and the
power evaluated for the present study size at 60 months.
Sequencing of large T-antigen stop codon region
For sequence information, the T-antigen region was amplified using
LongAmp Taq (New England Biolabs, Frankfurt, Germany) with the
primers 50-TCTGCGATGAATCACTTT-30, and 50-GTTGTATCAGGC
AAGCAC-30 and according to the manufacture’s protocol. The
amplicons were purified with the PCR purification kit (Qiagen) and
sequenced by the commercial vendor Seqlab (Goettingen, Germany).
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